FDA “Approvable” For Lev’s Cinryze Opens Window For Jerini To Reach Market First
This article was originally published in The Pink Sheet Daily
Executive Summary
Lev now targets mid-2008 for FDA approval for the C1 inhibitor for hereditary angiodema.